Literature DB >> 24891343

Neratinib Graduates to I-SPY 3.

.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24891343     DOI: 10.1158/2159-8290.CD-NB2014-055

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


× No keyword cloud information.
  6 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

Review 2.  The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.

Authors:  Donald A Berry
Journal:  Mol Oncol       Date:  2015-03-11       Impact factor: 6.603

3.  The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

Authors:  Angela DeMichele; Douglas Yee; Donald A Berry; Kathy S Albain; Christopher C Benz; Judy Boughey; Meredith Buxton; Stephen K Chia; Amy J Chien; Stephen Y Chui; Amy Clark; Kirsten Edmiston; Anthony D Elias; Andres Forero-Torres; Tufia C Haddad; Barbara Haley; Paul Haluska; Nola M Hylton; Claudine Isaacs; Henry Kaplan; Larissa Korde; Brian Leyland-Jones; Minetta C Liu; Michelle Melisko; Susan E Minton; Stacy L Moulder; Rita Nanda; Olufunmilayo I Olopade; Melissa Paoloni; John W Park; Barbara A Parker; Jane Perlmutter; Emanuel F Petricoin; Hope Rugo; Fraser Symmans; Debasish Tripathy; Laura J van't Veer; Rebecca K Viscusi; Anne Wallace; Denise Wolf; Christina Yau; Laura J Esserman
Journal:  Clin Cancer Res       Date:  2015-02-24       Impact factor: 12.531

4.  Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Authors:  Carlton L Schwab; Diana P English; Jonathan Black; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Beatrice Bussi; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-08-08       Impact factor: 5.482

Review 5.  Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.

Authors:  Daniel V T Catenacci
Journal:  Mol Oncol       Date:  2014-10-18       Impact factor: 6.603

6.  PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Authors:  M R Trusheim; A A Shrier; Z Antonijevic; R A Beckman; R K Campbell; C Chen; K T Flaherty; J Loewy; D Lacombe; S Madhavan; H P Selker; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2016-10-19       Impact factor: 6.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.